Levofloxacin prophylaxis for pediatric leukemia patients: monitoring of outcomes for sustained benefit and consequences

Andrea L Davis; Alexandra M Stevens; Julienne Brackett; Lucila Marquez; Catherine E Foster; Adriana Sarmiento Clemente; Hannah E Sauer; Grant T Stimes; Judith R Campbell

doi:10.1017/ash.2024.81

Levofloxacin prophylaxis for pediatric leukemia patients: monitoring of outcomes for sustained benefit and consequences

Antimicrob Steward Healthc Epidemiol. 2024 May 22;4(1):e90. doi: 10.1017/ash.2024.81. eCollection 2024.

Authors

Andrea L Davis¹, Alexandra M Stevens^{2

3}, Julienne Brackett^{2

3}, Lucila Marquez^{1

4}, Catherine E Foster^{1

4}, Adriana Sarmiento Clemente⁵, Hannah E Sauer⁶, Grant T Stimes⁷, Judith R Campbell^{1

4}

Affiliations

¹ Department Infection Control and Prevention, Texas Children's Hospital, Houston, TX, USA.
² Department of Pediatrics, Section of Hematology Oncology, Baylor College of Medicine, Houston, TX, USA.
³ Texas Children's Cancer Center, Texas Children's Hospital, Houston, TX, USA.
⁴ Department of Pediatrics, Division of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA.
⁵ Department of Pediatrics, Division of Infectious Diseases, Arkansas Children's Hospital, Little Rock, AR, USA.
⁶ Department of Global Pediatric Medicine, St. Jude Medical Center, Memphis, TN, USA.
⁷ Department of Pharmacy, Texas Children's Hospital, Houston, TX, USA.

Abstract

Levofloxacin prophylaxis reduces bloodstream infections in neutropenic patients with acute myeloid leukemia or relapsed acute lymphoblastic leukemia. A retrospective, longitudinal cohort study compares incidence of bacteremia, multidrug-resistant organisms (MDRO), and Clostridioides difficile (CDI) between time periods of levofloxacin prophylaxis implementation. Benefits were sustained without increasing MDRO or CDI.